2017 | 2016 | 2015
03/01/17Luminex Corporation To Present At The Barclays Global Healthcare Conference
AUSTIN, Texas, March 1, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Barclays Global Healthcare Conference to be held at the Loews Miami Beach Hotel March 14 - 16, 2017, in Miami Beach, FL. The investor presentation will begin at 4:20 p.m. Eastern time on Wednesday, March 15, 2017.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply... 
Printer Friendly Version
02/21/17Luminex Corporation Announces Initiation of Cash Dividend
AUSTIN, Texas, Feb. 21, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) (the "Company") today announced that its board of directors has authorized the initiation of a quarterly cash dividend to its shareholders, the first in the company's history.  This initial cash dividend will be payable on April 14, 2017 to shareholders of record as of the close of business on March 24, 2017. The board of directors intends for the Company to pay a regular quarterly cash dividend o... 
Printer Friendly Version
02/06/17Luminex Corporation Reports Fourth Quarter And Full Year 2016 Results
AUSTIN, Texas, Feb. 6, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and full year 2016 ended December 31, 2016.  Financial and operating highlights include the following: Consolidated fourth quarter and full year 2016 revenue of $72.3 million and $270.6 million, an increase of 20% and 14% compared to the fourth quarter and full year 2015.  In the fourth quarter, Nanosphere contributed revenue of $9.5 millio... 
Printer Friendly Version
01/09/17Luminex Announces Preliminary Revenue for Fourth Quarter 2016 and Issues 2017 Revenue Guidance; To Present at 35th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 9, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects revenues in the fourth quarter of 2016 to be approximately $72 million and approximately $271 million for the year. These results reflect increases of 20% and 14% compared to the respective periods in 2015. Verigene-related revenues in the fourth quarter were approximately $9 million, a 32% increase from the year ago period. The company conducted a reorganization in Decem... 
Printer Friendly Version
01/04/17Luminex Corporation Receives FDA Clearance for ARIES® GBS Assay
Sample to answer GBS assay offers higher sensitivity and specificity compared to culture AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group B Streptococcus (GBS) Assay for antepartum detection of GBS colonization in pregnant women. This is the third assay the FDA has cleared for use on the Luminex ARIES® Systems. The company has also achieved CE-IVD marking for the ARIES® GBS Assay... 
Printer Friendly Version